Fouad Elbaroudi, a graduate from Institut Polytechnique de Lorraine (France) as Engineer in mechanical sciences, founded in 1998 a first engineering company specialized in aeronautic. In 2001 he founded AXS INGENIERIE an innovative company focusing in numerical simulation for technologically advanced sectors in aeronautic and applied biomechanics. He created the concept of BIOMODTM and settled several clinical collaboration with key opinions leaders in spine surgery in France, Belgium and the US. He is the author of 3 patents. As the CEO of AXS MEDICAL he promotes the BIOMOD™ plateform that offers the 3D visualization solution that spine orthopedic surgeons, radiologists, physical and rehabilitation physicians are looking for to leapfrog to 3D spine imaging for a complete assessment of spinal deformities.

Dr. Herbert Köntges is an active investor and Board Member at MDW. He is responsible for Business Development and Marketing&Sales.  Prior to joining MDW, Herbert participated as a founding team member in three medical device start-up ventures that resulted in IPOs and subsequent buy-outs. This includes a general management role for a Cordis/J&J spin-off that was successfully sold to Pfizer. He is also a private investor in several medical device ventures. He has worked for over 25 years in sales/ marketing/ clinical research/ general management positions in international medical device companies in the EU and US.  His experience lies at the interface between product development and market introduction of new concepts in the medical device field.  He holds a PhD degree in Chemical Engineering from the TU-Berlin/ Germany and an MBA from INSEAD/ France and has received the innovation prize of the Brussels Chamber of Commerce.

Corinne Lebourgeois is co-founder of MedC. Partners, a leading consulting firm created in 2005 dedicated to the medical device industry which develops market access strategies that take into account key elements of Reimbursement, Marketing and Regulation. She has been working with more than 50 clients in Europe and in the US from start-ups, mid-size enterprises and corporations to financials groups. Corinne has a Bachelor of Sciences from the University of Lyon (ULCB) and an MBA from the University of Texas at Austin. In 2002, she graduated from UC Berkeley where she studied the new “e-economy”.  Corinne has twenty years’ professional experience in blue chip companies such as Johnson & Johnson, Ethicon, Gynecare and WL Gore. She managed product development from bench test to clinical, led groups of engineers and clinicians, and was able to introduce onto the market three of Ethicon best-selling innovative devices within three years. She also managed marketing units and closely worked with sales teams to promote innovative technologies. She has built medical device markets in Europe from scratch to multimillion dollar successes. She worked as a consultant for start-ups in the San Francisco Bay Area for several years, elaborating European market strategies.

Mr. Haig brings over 20 years of US, European and Asian experience in mature and early stage healthcare companies. His track record includes numerous successful product launches and pioneering commercialization and market development efforts in various fields such oral contraceptives, angioplasty devices, healthcare information, and radiation oncology. Prior to joining TriReme Medical in January of 2009, Mr. Haig was the VP, Marketing and Business Development with Calypso Medical Technologies, a privately held medical device company focused on improving the accuracy of external beam radiation therapy for cancer. Prior to joining Calypso, he spent 15 years in various marketing and business development roles of increasing responsibility with Guidant and Abbott Vascular. Most recently, Mr. Haig was the Director of Global Marketing for Drug Eluting Stents, which included responsibility for products such as Xience V and the next generation workhorse, bifurcation, and bioabsorbable stents. He earned an MBA from the Kenan-Flagler School of Business at the University of North Carolina and BA from the University of California at Berkeley.

Peter Rule joined OptiScan, Inc. in August of 2001 as Chairman of its board and as CEO in 2006. Prior to OptiScan, Mr. Rule has successfully led four venture backed companies.  Most recently, he served as Chairman and CEO of EKOS Corporation, from 2003-2005. Ekos has pioneered ultrasound assisted drug delivery for ischemic stroke and peripheral vascular disease.  Previously, Mr. Rule was President and CEO of PercuSurge and helped established a new niche in interventional cardiology:  embolic protection.  He joined the company in April 1996 as one of its first ten employees, selling it for $225 Million in 2000 to Medtronic, Inc.   While at PercuSurge, Peter was one of three founders of TheraSense, Inc., serving as the Chairman of the Board from 1996 to 1998. Previous to PercuSurge, Peter was President of MiniMed Incorporated, a provider of external pumps that deliver insulin for the treatment of Type I diabetes, and initiated the company’s now commercialized subcutaneous glucose sensor.  Peter joined MiniMed in 1985 also as one of its first ten employees, leaving in October 1995 after it had reached profitability, become over 325 employees worldwide, and successfully achieved an Initial Public Offering in July, 1995.  Peter was an industry advisor to the now famous Diabetes Control and Complications Trial (DCCT) during his time at MiniMed.

The First is free and open to all, yet prior registration is mandatory. The whole BioData event is paying (documents, cessions and lunches included). Rezonance Premium members benefit from a CHF 250.- discount. 

Don’t hesitate to forward this invitation.

Best regards

((( Rezonance

rezonance.ch - janvier 2010